Natural killer cells are part of our innate immune system providing direct and indirect mechanisms for killing cancer and an ideal foundation for off the shelf (allogeneic) cell therapy development.
Natural killer cells patrol our bodies looking for abnormal cells. They have an innate ability to recognize and and kill cancer cells without any priming or prior activation. (They’re named for this “natural” killing ability).
Natural killer cells are also able to produce cytokines that recruit and activate the immune system to mount an additional response to kill cancer cells.
Natural killer cells have fail-safe mechanisms that prevent the killing of healthy cells making them ideal for off the shelf platforms.
The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products.
The next generation CORE-NK platform will integrate additional activation and expansion features to further optimize the cancer-fighting power of the CORE-NK platform cells.
Development of the next generation CORE-NK platform will be as a combination therapy for blood cancers
CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen Receptor
CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen Receptor
CHM 3301 (Undisclosed CAR NK) will be developed on the next generation CORE-NK platform leveraging a currently undisclosed Chimeric Antigen Receptor
T cells are part of our adaptive immune system – the system that tailors the body’s response to specific pathogens. Rather than generically attack any antigens, T cells circulate until they encounter a specific antigen, playing a critical part in immunity to foreign substances.
Benefits of T Cell derived therapies may include:
Based upon evidence of CLTX binding in other solid tumours, preclinical studies are currently ongoing to determine the potential of CHM 1101 in solid tumours such as melanoma, colorectal cancer and prostate cancer.
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target CDH17.
Preclinical studies also demonstrated no toxicity to normal tissues.
Although CDH17 is known to be expressed on normal epithelial cells, the CDH17 CAR T cells only infiltrated the tumour cells, sparing the normal cells, even when they expressed CDH17.
In normal cells, CDH17 is inaccessible as it is hidden beneath tight junctions that reinforce the barriers of normal cells while in cancer, CDH17 upregulation results in exposure of the CDH17 on the cancer cells allowing the CAR T to detect and bind to it.
With the evidence of high CDH 17 expression in solid tumours, CHM 2101 is being studied in neuroendocrine tumours as well as in gastrointestinal (GI) cancers such as colorectal, pancreatic and gastric cancer.
Ongoing research collaboration with Dr David Wald, a clinician-scientist at Case Western Reserve University in Cleveland, Ohio.
Ongoing research collaboration with Dr Christine Brown and the Christine Brown Laboratory at the City of Hope Cancer Center.
Ongoing research collaboration with Dr Xianxin Hua and the Hua Laboratory at the University of Pennsylvania.
Chimeric is actively engaged in a strategic business development to further our mission to bring the promise of cell therapy to more patients with cancer.
We welcome inquiries on collaborating with us.
Cell therapy is the transfer of intact, live cells into a patient to help lessen or cure a disease.
The most common and simple type of cell therapy is a blood transfusion.
Other commonly known cell therapies include red and white blood cell transfusions and bone marrow transplants.
When the cells that are used for the therapy originate from the patient it is referred to as an autologous cell therapy.
When the cells that are used for the therapy originate from a donor it is referred to as an allogeneic cell therapy.
Autologous Chimeric Antigen Receptor (CAR) T cell therapy is a type of cell therapy in which a patient’s own T cells are reprogrammed in a laboratory to attack specific cancer cells.
CAR T cell therapies have shown transformative benefit in patients with blood cancers that have not responded or stopped responding to other therapies resulting in global approvals for CAR T cell therapies for certain types of Lymphoma, Leukemia and Multiple Myeloma.
Click icon to download
Poster PDF (1 MB)
or
Click on the image to see in Full screen
